Your browser doesn't support javascript.
loading
A retrospective study of 101 dogs with oral melanoma treated with a weekly or biweekly 6 Gy × 6 radiotherapy protocol.
Baja, Alexie J; Kelsey, Krista L; Ruslander, David M; Gieger, Tracy L; Nolan, Michael W.
Afiliación
  • Baja AJ; Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
  • Kelsey KL; Carolina Veterinary Specialists, Matthews, North Carolina, USA.
  • Ruslander DM; BluePearl Pet Hospital, Cary, North Carolina, USA.
  • Gieger TL; Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
  • Nolan MW; Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, USA.
Vet Comp Oncol ; 20(3): 623-631, 2022 Sep.
Article en En | MEDLINE | ID: mdl-35338766
One radiotherapy (RT) protocol used for canine oral melanoma (OM) gives 36 Gy total, in six weekly or biweekly fractions (6 Gy × 6). This retrospective study characterizes oncologic outcomes for a relatively large group of dogs treated with this protocol and determines whether radiation dose intensity (weekly vs. biweekly) affected either progression-free or overall survival (PFS and OS). Dogs were included if 6 Gy × 6 was used to treat grossly evident OM, or if RT was used postoperatively in the subclinical disease setting. Kaplan-Meier statistics and Cox regression modelling were used to determine the predictive or prognostic value of mitotic count, bony lysis, World Health Organization (WHO) stage (I, II, III, or IV), using systemic anti-cancer therapies, tumour burden at the time of RT (macroscopic vs. subclinical), radiation dose intensity (weekly vs. biweekly), and treatment planning type (manual vs. computerized). The median PFS and OS times for all dogs (n = 101) were 171 and 232 days, respectively. On univariate analysis PFS and OS were significantly longer (p = <.05) with subclinical tumour burden, WHO stages I or II, and weekly irradiation. On multivariable analysis, only tumour stage remained significant; therefore, cases were grouped by WHO stage (I/II vs. III/IV). With low WHO stage (I/II), PFS and OS were longer when irradiating subclinical disease (PFS: risk ratio = 0.449, p = .032; OS: risk ratio = 0.422, p = .022); this was not true for high WHO stage (III/IV). When accounting for other factors, radiation dose intensity had no measurable impact on survival in either staging group.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Boca / Enfermedades de los Perros / Melanoma Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: Vet Comp Oncol Asunto de la revista: MEDICINA VETERINARIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Boca / Enfermedades de los Perros / Melanoma Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Animals Idioma: En Revista: Vet Comp Oncol Asunto de la revista: MEDICINA VETERINARIA / NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido